Global Shortage of Hepatitis B Vaccine
Supplies of some vaccines for hepatitis B continue to be limited. In particular those that provide a combined vaccination against hepatitis A and hepatitis B are in limited supply.
People eligible for publicly funded hepatitis B vaccine under the National Immunisation Program or state & territory government programs should have no difficulty but those who fall outside these programs may still experience delays in obtaining the vaccine as supplies are slowly being returned to normal. Those people requiring vaccination against hep A and hep B (eg. traveling to places were contracting hep A or hep B is more likely) may need to have seperate injections for each virus.
If you are experiencing any difficulties please call 1800 437 222 for more information regarding hepatitis B vaccinations in your state or territory.
The latest information about shortages of vaccines and other medicines is available at the Therapeutic Good Administration website
Hepatitis B can be prevented with a safe and effective vaccine that has been available since 1982. In Australia, the hepatitis B vaccination program commenced in 1988, targeting groups at particularly high risk of infection. It is now recommended that all babies and adolescents be vaccinated against hepatitis B. The program continues and ensures that babies and adolescents have access to free hepatitis B vaccine.
The Australian Immunisation Handbook (updated June 2015) recommends that the following groups are vaccinated against hepatitis B:
babies and young children
household contacts (other than sexual partners) of people with acute and chronic hepatitis B
sexual contacts of people with acute and chronic hepatitis B
dialysis patients and people with impaired renal function in whom dialysis is anticipated
Individuals with HIV and other adults with weakened immune systems
Aboriginal and Torres Strait Islander people*
people who have migrated from countries where hepatitis B is endemic*
people who inject drugs *
sex industry workers*
men who have sex with men*
recipients of certain blood products *
individuals with chronic liver disease and/or hepatitis C *
residents and staff of facilities for persons with intellectual disabilities *
individuals adopting children from overseas
liver transplant recipients *
inmates and staff from long-term correctional facilities *
healthcare workers, dentists and all people directly involved in patient care and/or the handling of human tissue, blood or body fluids
others at risk including:
police, members of the armed services and emergency services staff
long-term travellers to regions with high endemicity
staff of child day-care centres
people playing contact sport.
embalmers, tattooists and body-piercers
* Individuals should consider the combined hepatitis A/hepatitis B vaccine.
Children born after the 1st of May 2000 receive hepatitis B vaccine shortly after birth while they are in hospital and further doses at 2, 4 and 6 months of age.
Children in Year 7 or adolescents aged between 11 and 15 years receive a two-dose course of adult hepatitis B vaccine given 4 to 6 months apart.
In order to obtain maximum protection against hepatitis B, adults should receive three doses of the vaccine at zero, 1 and 6 months intervals.
A post-vaccination blood test, to assess if the vaccine course has been effective in producing protection against hepatitis B infection, is recommended four weeks after the third dose of the hepatitis B vaccine for people in the following categories: some would say all adults!
people at significant occupational risk (e.g. healthcare workers whose work involves frequent exposure to blood and body fluids)
people at risk of severe or complicated disease (e.g. people with pre-existing liver disease not related to hepatitis B and adults with weakened immune systems)
people in whom a poor response to the hepatitis B vaccination is expected.
Side effects of the hepatitis B vaccine are not common, however, a small number of people report pain at the injection site and/or a mild fever after the injections
National Health and Medical Research Council (NHMRC) 2015. The Australian Immunisation Handbook 2015 10th Edition (with updates). www.immunise.health.gov.au
.Therapeutic Good Administration 2017 - Hepatitis B surface antigen recombinant - medicine shortage information.